Thus, the aim of the present study was to evaluate the 18-month safety and effectiveness of DU 1.5 mg/once weekly as add-on therapy to MET or a combination of MET plus conventional insulin secretagogues in a patient cohort with T2D and overweight/obesity attending our endocrinology outpatient clinic. The gene discussed is INS; the disease is Obesity.